scholarly article | Q13442814 |
P50 | author | Laurie Gutmann | Q38589707 |
William J Meurer | Q43161011 | ||
Thomas Tomsick | Q87999626 | ||
Sidney Starkman | Q110243430 | ||
P2093 | author name string | Jane Khoury | |
Scott E Kasner | |||
Steven R Levine | |||
Steven Warach | |||
Joseph P Broderick | |||
Phillip A Scott | |||
Alexander Schneider | |||
Dawn Kleindorfer | |||
Opeolu Adeoye | |||
Brett C Meyer | |||
James S McKinney | |||
Thomas M Hemmen | |||
Heidi Sucharew | |||
Claudette E Brooks | |||
Sharyl Martini | |||
Arthur M Pancioli | |||
Todd J Crocco | |||
William A Knight | |||
Pamela A Schmit | |||
CLEAR-ER Investigators | |||
P2860 | cites work | Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial | Q28185728 |
Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | Q30810700 | ||
Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. | Q34159021 | ||
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial | Q36986795 | ||
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial | Q40744288 | ||
Calibrated phase II clinical trials in oncology | Q41477121 | ||
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial | Q43188064 | ||
Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial | Q44237164 | ||
Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? | Q48859420 | ||
Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) | Q79936656 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | plasminogen | Q107129060 |
P304 | page(s) | 2381-2387 | |
P577 | publication date | 2013-07-25 | |
P1433 | published in | Stroke Journal | Q7624282 |
P1476 | title | Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial | |
P478 | volume | 44 |
Q33671141 | A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke |
Q42857714 | Adjunctive medical therapies for acute stroke thrombolysis: is there a CLEAR-ER choice? |
Q38127644 | Advances and challenges in treatment and prevention of ischemic stroke |
Q34459133 | Advances in medical revascularisation treatments in acute ischemic stroke |
Q38261206 | Alteplase in acute ischemic stroke: putting the guidelines into practice |
Q40523644 | An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke |
Q38790291 | Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy. |
Q38243696 | Clinical trials in acute ischemic stroke |
Q35998267 | Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial |
Q50053948 | Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update. |
Q38786616 | Effect of waivers of consent on recruitment in acute stroke trials: A systematic review |
Q48458092 | Emergency and critical care management of acute ischaemic stroke |
Q93081135 | From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent |
Q51060040 | Glycoprotein IIb/IIIa Inhibitor Bridging and Subsequent Endovascular Therapy in Vertebrobasilar Occlusion in 120 Patients. |
Q26797275 | Imaging of prehospital stroke therapeutics |
Q38225341 | Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications |
Q41678659 | Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard? |
Q89563727 | Mobile Stroke Units: Bringing Treatment to the Patient |
Q39106145 | Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. |
Q37670794 | Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research |
Q35019813 | Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis |
Q38170691 | Stroke: new horizons in treatment |
Q33417854 | Targeting integrin and integrin signaling in treating thrombosis |
Q38541197 | Treatment of acute stroke: an update |
Q90538834 | Update in the Early Management and Reperfusion Strategies of Patients with Acute Ischemic Stroke |
Q48558308 | Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke. |
Q26796472 | What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention? |
Search more.